OMER
resolvedOmeros Corporation
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Omeros Corporation's ~10% gap up likely reflects a meaningful de-risking event around its commercial and regulatory trajectory. The company's core revenue driver, Omidria (used in cataract surgery), has been building toward sustained profitability, and any commentary from management reinforcing Omidria's revenue durability or gross margin expansion would be a clear positive. Additionally, Omeros has carried significant overhang from its narsoplimab (OMS721) Complete Response Letter and broader pipeline uncertainty — any incremental regulatory clarity or strategic maneuvering could trigger a sharp short-covering rally given the stock's historically high short interest and small float. The low volume on the gap (0.14x average) is notable and suggests this may be driven more by thin sell-side liquidity and a lack of sellers than by aggressive institutional accumulation. That said, for a micro-cap biotech like Omeros, even modest positive developments — whether related to Omidria prescription trends, cash runway extension, FDA dialogue progress, or settlement of outstanding legal/arbitration matters — can catalyze a disproportionate repricing. Wall Street would reprice OMER higher if management signals a credible path toward sustainable free cash flow generation or a resolution of the narsoplimab regulatory overhang that unlocks pipeline optionality at minimal additional capital spend.
Analyzed by rerate-v2+glm-5.2 · Jul 27, 2026
Catalysts
- Omidria revenue growth and gross margin improvement signaling path to operational profitability
- Regulatory progress on narsoplimab resubmission strategy or Type A meeting outcomes with FDA
- Extended cash runway through cost discipline, partnership, or non-dilutive financing
- Pipeline advancement of OMS906 or other complement-mediated programs creating optionality value
- Resolution of outstanding litigation or arbitration reducing balance sheet uncertainty
- Potential short squeeze dynamics given historically elevated short interest in OMER
Risks
- Low volume gap (0.14x avg) suggests weak conviction — reversal risk is elevated
- Narsoplimab remains a high-risk asset with unresolved FDA Complete Response Letter issues
- Cash burn and potential need for dilutive capital raise remain persistent concerns
- Small float and micro-cap dynamics amplify volatility in both directions
- Omidria faces competitive pressure from compounded alternatives and potential reimbursement headwinds
- No clear technical confirmation — stock has not reclaimed 200-SMA and remains near short-term moving averages
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $11.28 | $11.29 | $10.58 | 2.22M |
| Day 2 | $11.67 | $11.89 | $11.24 | 1.69M |
| Day 3 | $11.93 | $12.16 | $11.63 | 1.32M |
| Day 4 | $11.84 | $11.99 | $11.37 | 1.31M |
| 📍 Day 5 | $12.56 | $12.59 | $11.90 | 1.45M |
Signal Breakdown
Gap held — only 0% erased, price maintained gains
Moderate volume decline (35%)
Higher highs with peak close on day 5 — continued buying interest
Moderate drawdown (4.3%)
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026